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Abstract  
Loss or mutation of the tumour suppressor Merlin predisposes individuals to develop multiple 
nervous system tumours, including schwannomas and meningiomas, sporadically or as part 
of the autosomal dominant inherited condition Neurofibromatosis 2 (NF2). These tumours 
display largely low grade features but their presence can lead to significant morbidity. 
Surgery and radiotherapy remain the only treatment options despite years of research, 
therefore an effective therapeutic is required.   
Unbiased omics studies have become pivotal in the identification of differentially expressed 
genes and proteins that may act as drug targets or biomarkers. Here we analysed the proteome 
and phospho-proteome of these genetically defined tumours using primary human tumour 
cells to identify upregulated/activated proteins and/or pathways. We identified over 2000 
proteins in comparative experiments between Merlin-deficient schwannoma and meningioma 
compared to human Schwann and meningeal cells respectively. Using functional enrichment 
analysis we highlighted several dysregulated pathways and Gene Ontology terms. We 
identified several proteins and phospho-proteins that are more highly expressed in tumours 
compared to controls. Among proteins jointly dysregulated in both tumours we focused in 
particular on PDZ and LIM domain protein 2 (PDLIM2) and validated its overexpression in 
several tumour samples, while not detecting it in normal cells. We showed that shRNA 
mediated knockdown of PDLIM2 in both primary meningioma and schwannoma leads to 
significant reductions in cellular proliferation. 
To our knowledge, this is the first comprehensive assessment of the NF2-related meningioma 
and schwannoma proteome and phospho-proteome. Taken together, our data highlight several 
commonly deregulated factors, and indicate that PDLIM2 may represent a novel, common 
target for meningioma and schwannoma.  
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Introduction  
Neurofibromin 2 (Merlin, NF2) is a tumour suppressor protein expressed during embryonic 
development and thereafter (Gronholm et al., 2005). In adults, significant levels of expression 
are found in Schwann and meningeal cells, nerve and lens (Claudio et al., 1997; Sakuda et al., 
1996; Scherer & Gutmann, 1996). Mutations in the encoding gene (NF2) lead to formation of 
schwannomas and meningiomas, and less often of ependymomas and retinal astrocytic 
hamartomas (Hanemann, 2008; Martin et al., 2010; Rouleau et al., 1993). These tumours 
originate sporadically or as part of the genetic condition Neurofibromatosis type 2 (NF2) 
(Hanemann, 2008). They are largely unresponsive to classic chemotherapeutic agents, 
leaving surgery and radiotherapy as the only remaining treatment options which can leave the 
patient with mild to severe morbidity (Hanemann, 2008). Additionally, NF2 patients often 
develop multiple tumours simultaneously (Hanemann, 2008), strengthening the need for 
effective systemic therapeutic options. Loss of Merlin has also been related to a variety of 
other cancers, including glioblastomas, malignant mesotheliomas and thyroid carcinomas, 
highlighting its role as tumour suppressor (Garcia-Rendueles et al., 2015; Guerrero et al., 
2015; Lee et al., 2016; Morrow et al., 2016; Sheikh et al., 2004). 
Merlin shares structural similarity with the Ezrin/Radixin/Moesin (ERM) family of 
proteins that link the cytoskeleton with components of the cell membrane (Bretscher et al., 
2000; McClatchey, 2003; McClatchey & Giovannini, 2005). Although Merlin lacks the C-
terminal actin-binding domain present in the other members of the ERM family, it can 
localize to the cortical cytoskeleton and interact directly with the actin-binding protein α-
catenin (Gladden et al., 2010). At sites of cell-cell contact Merlin acts as tumour suppressor 
controlling cadherin-mediated contact-dependent inhibition of proliferation and adherens 
junction formation (Flaiz et al., 2008; Lallemand et al., 2003). Several receptor tyrosine 
kinases (RTKs) have been found to be Merlin-dependent (Curto et al., 2007; Lallemand et al., 
2009). Our group and others showed overexpression and reduced degradation of the platelet-
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derived growth factor receptor β (PDGFRβ) in schwannoma compared to normal Schwann 
cells which, together with the loss of Merlin, leads to increased cellular proliferation and 
aberrant activation of  the  MAPK and PI3K signalling pathways (Ammoun et al., 2008; 
Fraenzer et al., 2003). RTKs are found to be linked to Merlin and thus the cytoskeleton via 
the PDZ domain–containing adapter NHERF-1 (Na+/H+ exchanger regulatory factor) 
(Maudsley et al., 2000; Weinman et al., 2000). Merlin loss further contributes to 
tumorigenesis via the activation of a number of other pathways including the Hippo, Ras and 
Wnt/ β-catenin (Li et al., 2014; Mohler et al., 1999; Zhao et al., 2010; Zhou et al., 2011). 
Merlin activity is also in the nucleus, where it binds to the E3 ubiquitin ligase CRL4 (DCAF1) 
suppressing its activity. Depletion of DCAF1 in Merlin-deficient schwannoma cells was 
sufficient to block proliferation (Cooper et al., 2011).  
Unbiased genomic studies have been performed aiming to identify novel differentially-
expressed genes in schwannomas and meningiomas (Fevre-Montange et al., 2009; Hanemann 
et al., 2006; Torres-Martin et al., 2013a; Torres-Martin et al., 2013b; Torres-Martin et al., 
2014; Wang et al., 2012) as well as novel driver mutations, exclusive of NF2 (Clark et al., 
2013).  
Mass spectrometry (MS) is a powerful, high-throughput technique to identify thousands of 
proteins aberrantly expressed and regulated. Recently Sharma and colleagues performed 
comparative proteomic analysis on different grades of meningiomas to investigate alterations 
in the meningioma tissue and in the human serum of meningioma patients compared to 
normal brain tissue. They identified several deregulated proteins including transgelin-2 and 
caveolin in tissue, plus apoliopoproteins A and E in serum (Sharma et al., 2014; Sharma et al., 
2015).  
Here we analysed by label free quantitative proteomics both the proteome and phospho-
proteome of meningioma and schwannoma primary tumour cells. By analysing proteomes 
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and phospho-proteomes together, we identify overexpressed proteins in tumour cells and 
regulatory signalling pathways that may be ‘switched off’ with therapeutic intervention.   
We also compared protein abundancies in primary Merlin-deficient human meningioma 
cells against human meningeal cells, and primary human schwannoma cells against primary 
human Schwann cells. We identified numerous novel upregulated and downregulated 
proteins and phospho-proteins, performed Gene Ontology (GO) mapping and functional 
enrichment analyses for GO and pathway terms. We identified proteins common to both 
Merlin-deficient tumour types. Several of the upregulated proteins contained either a 
PDZ/LIM domain, or both. These proteins have been shown to have a wide range of 
biological functions including roles in cell signalling (Te Velthuis et al., 2007). We found 
PDZ and LIM domain protein 2 (PDLIM2/ mystique/SLIM) commonly upregulated in both 
tumour types compared to the normal controls. Previous experiments on PDLIM2 suggested 
a role in cytoskeletal organization as it was co-immunoprecipitated together with alpha-
actinin-1, alpha-actinin-4, filamin A, and myosin heavy polypeptide 9 in rat corneal epithelial 
cells (Loughran et al., 2005a; Torrado et al., 2004). PDLIM2 was also identified at the 
nuclear level exerting tumour suppressive functions by terminating NF-κB activation during 
inflammation (Tanaka et al., 2007) and in breast cancer (Qu et al., 2010). PDLIM2 
overexpression was found in metastatic cancer cells (Loughran et al., 2005b) and androgen-
independent prostate cancer cell lines (Kang et al., 2016). Using our primary human cultures 
we performed PDLIM2 silencing in primary human schwannomas and meningiomas and 
observed a statistically significant reduction in cell proliferation in both tumour types. 
To our knowledge, this work is the first proteomic study aiming to decipher common 
deregulated elements in the proteome and phospho-proteome of Merlin-deficient 
schwannomas and meningiomas.  
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Materials and methods 
Clinical samples  
Meningioma and schwannoma specimens were collected after patients consented to the study 
and given a unique MOT identification number. This study was granted full national ethics 
approval by the South West research ethics committee (REC No: 14/SW/0119; IRAS project 
ID: 153351) and local research and development approval (Plymouth Hospitals NHS Trust: 
R&D No: 14/P/056 and North Bristol NHS Trust: R&D No: 3458). Normal human Schwann 
cells were collected after ethical approval under the REC number  REC6/Q2103/123. The 
brain tumour material was obtained from the Imperial brain tumour bank and this sub-
collection is covered by Imperial College Tissue bank ethics. All meningioma samples used 
in this study were grade I.  
Cell culture  
Human meningeal cells (HMC) were obtained from Sciencell™ and maintained in the 
manufacturer’s recommended media at 5% CO2. Human primary Schwann/schwannoma cells 
were maintained as described previously (Rosenbaum 2000). Ben-Men-1 cells and primary 
meningioma cells were routinely grown in DMEM, 10% FBS and 100U/ml 
Penicillin/Streptomycin, and were kept at 5% CO2/37 
o
C.  
Phospho-protein Purification 
Phospho-proteins were isolated from cell lysates using the commercially available phospho-
protein purification kit from Qiagen®. The manufacturers reported an enrichment of over 80% 
with less than 5% phosphorylation in the flow-through fraction. Similarly Meimoun et al. 
reported an enrichment of 88% using this kit (Meimoun et al., 2007). The protocol was 
carried out according to the manufacturer’s instructions using 2.5 mg of starting material. 
Protein concentrations were determined by the BCA protein assay according to the 
manufacturer’s instructions. 
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In-gel Digestion 
Cells were lysed in the buffer provided with the phospho-protein purification kit. 50 µg of 
protein and corresponding isolated phospho-protein were separated via SDS-PAGE. Gels 
were stained with colloidal coomassie blue stain (Life Technologies) for 3 hours at room 
temperature (RT). Destaining was performed using MS grade water (Fisher) overnight at RT. 
Individual lanes were cut into small 1 mm x 1 mm pieces before in-gel digestion as described 
previously (Lasonder et al., 2002). The protocol was performed as follow per slice: 
equilibration in 200 µl of 50 mM ammonium bicarbonate (ABC) for 5 minutes at 37 
o
C, 
destaining in 200 µl of 50% acetonitrile (ACN)/50% H2O for 5 minutes at 37 
o
C  then 200µl 
of 100% ACN for 5 minutes at 37 
o
C. These steps were performed in triplicate. 200 µl of 
reduction buffer (10 mM dithiothreitol in ABC) was added to the gel slices and incubated for 
20 minutes at 56 °C. Slices were then shrunk using 100% ACN for 5 minutes at RT and 
alkylated using 200 µl of alkylation buffer (23.35 mg 2-choloroacetamide, 5 ml 50 mM ABC) 
for 20 minutes at RT in the dark. The gel pieces were incubated with digestion buffer (12.5 
ng/µl trypsin in ABC) overnight at 37 °C. Digested peptides were extracted by the addition of 
2% Trifluoroacetic acid (TFA) to the digestion buffer incubated for 20 minutes on a shaker at 
37 
o
C. Peptide solutions were transferred to fresh tubes, and 100 µl of buffer B (80% ACN, 
0.5% acetic acid, 1% TFA) was added to the gel pieces and incubated for a further 20 
minutes on a shaker at 37 
o
C. The buffer B solution was then combined with the solution 
from the first peptide extraction, and samples were concentrated in a DNA centrifuge 
(Labconco centrivap®) until less than 40 µl of sample was left. Samples were then dissolved 
in buffer A (0.5% acetic acid, 1% TFA) prior to MS analysis. 
Peptide purification with Stage Tips 
Stage tips were assembled by placing high performance C18 extraction disks into pipette tips 
as described (Rappsilber et al., 2003). 50 µl of methanol was added to the prepared stage tips 
and centrifuged until the whole volume passed through. This was repeated with buffer B (80% 
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acetonitrile, 0.5% acetic acid) and then twice with buffer A (0.5% acetic acid). Samples were 
added to stage tips and centrifuged (1 minute; 10,000xg at RT). 50 µl of buffer A was then 
added and centrifuged until all the volume had passed through. Peptides were eluted by 
addition of 20 µl of buffer B and centrifugation. The samples were concentrated using a 
speed vac before resuspension in buffer A to give a final volume of approximately 25 µl 
(Rappsilber et al., 2003).  
Liquid Chromatography Tandem Mass Spectrometry 
MS was carried out using an Ultimate 3000 UPLC system (Thermo Fisher,Germany) 
connected to an Orbitrap Velos Pro mass spectrometer (Thermo Fisher,Bremen,Germany). 
The prepared peptides were loaded on to a 2 cm Acclaim™ PepMap™100 Nano-Trap 
Column (Thermo Fisher, Germany) and separated by a 25 cm Acclaim™ PepMap™100 
Nano LC column (Thermo Fisher, Germany) packed with C18 beads of 3 µm and running a 
120 minutes gradient of 95 % buffer A/5% buffer B (buffer A contains 0.5% acetic acid and 
buffer B contains 0.5% acetic acid in 100% acetonitrile) to 65% buffer A/35 % buffer B and a 
flow rate of 300 nl/minute. Eluted peptides were electrosprayed into the mass spectrometer at 
a spray voltage of 2.5 kV. The Orbitrap instrument performs data acquisition in a data 
dependent mode to switch between MS and MS2. The Orbitrap cell with a resolution of 
60,000 acquires a full-scan MS spectrum of intact peptides (m/z 350–1500) with an 
automated gain control accumulation target value of 1,000,0000 ions. In the linear ion trap 
the ten most abundant ions are isolated and fragmented by applying collision induced 
dissociation using an accumulation target value of 10,000, a capillary temperature of 275 °C, 
and normalized collision energy of 30%.  A dynamic exclusion of ions previously sequenced 
within 45 seconds was applied. Any singly charged ions and unassigned charged states were 
excluded from sequencing and a minimum of 10,000 counts was required for MS2 selection. 
Dynamic exclusion is a widely used tool in mass spectrometry data acquisition software 
enabling more proteins to be identified and increase proteome coverage (Zhang et al., 2009).  
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 Protein Identification   
Andromeda search engine integrated in MaxQuant version 1.3.05 programme was used to 
identify the proteins in the Uniprot database (www.uniprot.org/downloads, November 2015) 
and supplemented with sequences of frequently observed contaminants. A mass tolerance of 
6 ppm for the parental peptide and 0.5 Da for fragmentation spectra and a trypsin specificity 
allowing up to 2 mis-cleaved sites were set as the Andromeda search parameters. Fixed 
modifications of carboxyamidomethylation of cysteines and variable modifications of 
oxidation of methionine, deamidation of glutamine and asparagine were set.  A minimal 
peptide length of 7 amino acids was set. MaxQuant performed an internal mass calibration of 
measured ions and peptide validation by the target decoy approach as described. Proteins and 
peptides with a better than 1% false discovery rate (FDR) were accepted if they had been 
identified by at least 2 peptides in one of the samples. Shared peptide sequences (razor 
peptides) were mapped to proteins by the principle of maximum parsimony in MaxQuant. 
Proteins were quantified by normalised summed peptide intensities computed as label free 
quantification (LFQ) values in MaxQuant 1.3.05 ￼(Cox et al., 2014)LFQ data was generated 
in triplicate for all samples. LFQ data was generated in triplicate for all samples. 
Quantification analysis 
LFQ data generated by Maxquant were processed using Microsoft Excel and specially 
developed proteomics software, Perseus (Tyanova et al., 2016). LFQ values for proteins and 
phospho-proteins were Log2 transformed and fold change (FC) was calculated based on the 
equation: Average Log2 LFQ tumour - Average Log2 LFQ control. Entries with 0 for LFQ 
were kept and included in the fold change calculations. A 2 sample t-test was performed 
generating p-values for each identified protein/phospho-protein. The proteins with a p-value 
<0.05 were considered differentially expressed and included in further analysis. Significantly 
changed phospho-proteins were compared against respective protein changes to identify those 
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that are relatively highly upregulated i.e. displaying a large significant change in 
phosphorylation and a smaller increase or a decrease in protein abundance.  
Functional Enrichment Analysis  
Functional enrichment analysis was performed using Benjamini-Hochberg multiple 
correction testing integrated in to the database for annotation, visualization and integrated 
discovery (DAVID) software (Huang da et al., 2009) for Gene Ontology (GO) annotations 
and for KEGG pathways annotations. Functional enrichment analysis compares coverage of 
GO and pathway terms from significantly differentially expressed proteins with coverage of 
these terms in a defined control background – in this case the entire human proteome. This 
allows pathways, biological processes, molecular functions and proteins of particular cellular 
components to be identified that are proportionally over represented in the experimental 
dataset than they are in the background dataset and calculated as fold enrichment. We 
accepted enriched GO and pathway terms with p adjusted < 0.05 and Fold Enrichment > 2. 
The representative steps involved in target identification are presented in figure S1.  
Western Blotting 
Cells were lysed in RIPA buffer consisting of (150 mM NaCl, 1% Triton-X, 0.5% Sodium 
deoxycholate, 0.1% SDS and 50 mM Tris pH 8.0) before protein concentration was 
determined using a colorimetric BCA protein assay (Pierce), and immunoblotting proceeded 
as described previously (Kaempchen et al., 2003). Samples intended for MS measurement 
were separated using 4-15% gradient pre-cast gels (Bio-rad). The antibodies used in the study 
included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from 
Cell Signaling Technology; PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH 
(1:50.000) from Millipore. 
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Immunofluorescence microscopy 
For immunofluorescence, cells were grown O/N on glass slides. The following day slides 
were washed twice with PBS and fixed with 4% Paraformaldehyde (PFA)/PBS for 10 
minutes. Slides were then washed twice with PBS and cells were permeabilized with 0.2% 
Triton X-100/PBS for 5 minutes at RT. Slides were washed three times with PBS and 
blocked for 1 hour in 10% BSA/PBS at RT. Primary antibodies were diluted in 5% BSA/PBS 
and incubated O/N at 4 C. Slides were then washed thrice in PBS for 5 minutes each and 
incubated with secondary antibodies (1:200, Alexa Fluor®, Life Technologies), nuclear 
counterstained (DAPI, 4µg/ml) and mounted with ProLong Diamond antifade mountant (Life 
Technologies). Confocal microscopy was performed using a Leica DMI6000B microscope. 
shRNA Mediated Gene Silencing 
Cultured cells were seeded at 80% confluency before transfection with lentiviral particles (10 
μl/6 well, 2 μl labtek) directed towards PDLIM2 (Sigma) in the presence of 5 μg/ml 
polybrene (Santa Cruz biotechnology). Lentivirus was applied for 24 hours, at which point 
medium was removed and replaced with normal medium for a further 24 hours. Puromycin 
was then applied to cells at a concentration of 5 μg/ml for cell selection. Selection took place 
over 4-5 days, at which point cells were lysed for Western blot analysis, or fixed and stained 
for Ki-67 expression. Five different shRNA clones were tested (sequence clone 1: 
CCGGCTCGGAAGTCTTCAAGATGCTCTCGAGAGCATCTTGAAGACTTCCGAGTTT
TTTG; sequence clone 2: CCGGGCTCTTACATGAGCTAAGTTTCTCGAGAAACTTAGC 
TCATGTAAGAGCTTTTTTG; sequence clone 3: CCGGGAGGACATACACTGAGAGTC 
ACTCGAGTGACTCTCAGTGTATGTCCTCTTTTTTG; sequence clone 4: CCGGCCAC 
TGCCTTTGATCAACCTTCTCGAGAAGGTTGATCAAAGGCAGTGGTTTTTTG; 
sequence clone 5: CCGGGAGCTGTACTGTGAGAAGCATCTCGAGATGCTTCTCACA 
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GTACAGCTCTTTTTTG), cloned into the plasmid pLKO.1-puro. Clone 5 was the most 
successful in knocking down PDLIM2. 
-Phosphatase treatment and Cytoplasmic-Nuclear Extraction 
Cells were lysed in RIPA buffer containing protease inhibitors but not phosphatase inhibitors. 
Protein dephosphorylation was achieved by treating 20 µg of protein lysate with -
phosphatase (New England Biolabs) following the instructions of the supplier. The reaction 
was allowed to proceed for 2 hours at 30 °C. Non treated sample was incubated in the same 
buffer and for the same amount of time at 30 °C but water was added in place of -
phosphatase. 
To ascertain the cellular location of PDLIM2, a cytoplasmic and nuclear extraction assay 
(Thermo Scientific) was performed. Primary adherent meningioma cells were harvested with 
trypsin and centrifuged at 500 g for 5 minutes. The cell pellet was then washed once in PBS, 
transferred to a micro centrifuge tube and centrifuged for 3 minutes at 500 g. Ice cold CER I 
reagent (Cytoplasmic Extraction Reagent, provided with the kit) was added to the pellet, 
vortexed vigorously for 15 seconds and incubated on ice for 10 minutes. Ice cold CER II was 
then added to the tube and vortexed for 5 seconds on the highest setting before incubation on 
ice for 1 minute. The tube was then centrifuged for 5 minutes at 16000 g and the supernatant 
immediately transferred to a pre-chilled tube (the cytoplasmic fraction). Ice cold NER 
(Nuclear Extraction Reagent, provided with kit) was added to the remaining pellet and 
vortexed for 15 seconds. After incubation on ice for 40 minutes with rigorous vortexing every 
10 minutes, the tube was centrifuged at maximum speed for 10 minutes. The supernatant 
(nuclear fraction) was transferred to a clean tube and both extracts were stored at -80
o
C until 
analysis by Western blot. The experiment was repeated in triplicate on three different 
meningioma cell populations. Total HDAC1 and GAPDH were included as reference proteins 
for the nuclear and cytoplasmic fractions respectively.  
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Results  
Differential protein and phospho-protein expression in Schwannoma vs. Schwann Cells 
Three primary Merlin-deficient schwannoma-derived cell populations were analysed vs. 
human primary Schwann cells. Merlin status was confirmed by Western blot prior to MS 
analysis (Fig. 1A). The global proteome and the isolated phospho-proteome were measured in 
parallel to allow an indirect comparison between proteome and phospho-proteome data, and 
also to identify both phosphorylated and non-phosphorylated potential targets. Over 1559 
proteins (Table S1a) (peptides in table S1c) and over 2455 phospho-proteins (Table S1b) 
(peptides in table S1d) were identified in primary schwannoma vs. Schwann cells with a 32% 
overlap (Fig. S5a). Only 16 proteins in the proteome dataset were found to be significantly 
upregulated with a Log2FC >1, while 93 proteins were downregulated with a Log2FC <-1. A 
list of the significant differentially expressed proteins is summarized in table S2. The top 
three upregulated include the fructose-bisphosphate aldolase C (ALDOC), the proteasome 
subunit beta type-5 (PSMB5) and transgelin (TAGLN), the latter identified also in previous 
studies (Sharma et al., 2015). All upregulated proteins were grouped based on protein class 
and are represented by a pie chart (Fig. 1B). The largest proportion of upregulated proteins 
were cytoskeletal (50%). Interestingly, 11 of the 16 upregulated proteins interact with one 
another, as identified by string.db (Fig. S3). In the phospho-proteome dataset, 122 were 
significantly upregulated with a log fold-change over 1 and 101 phospho-proteins were 
significantly downregulated with a Log2FC <-1 (Table S3). Among the most upregulated 
phospho-proteins was the Yorkie homolog (YAP), previously shown to be active in 
schwannoma (Li et al., 2014) as well as members associated to the Ras pathway (Ammoun et 
al., 2008; Morrison et al., 2007). 
In order to identify individual proteins aberrantly regulated that may be involved in protein 
signalling and pathway activation, we analysed the phospho-proteome dataset with respect to 
whole pathways and/or biological processes that are significantly represented using DAVID 
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(Huang da et al., 2009). The upregulated phospho-proteins were mapped to several pathways 
(Fig. 1C). Among the statistically enriched pathways (Benjamini-Hochberg Adjusted p<0.05) 
represented by the upregulated proteins were focal adhesion (18%, Fold enrichment (FE) 5), 
the MAPK pathway (16%, FE 3) and regulation of the actin cytoskeleton (12%, FE 3), 
pathways that have previously been shown to be activated in schwannoma (Ammoun et al., 
2014; Schulze et al., 2002). Among the other deregulated pathways identified were 
endocytosis (12%, FE 3), vascular smooth muscle contraction (12%, FE 6), neurotrophin 
signalling (9%, FE 4), glycolysis/gluconeogenesis (7%, FE 6). We also performed functional 
enrichment analysis on the upregulated phospho-protein dataset to identify the most 
significant GO terms (Fig. 1D). RAS protein signal transduction was identified as the most 
enriched biological process in line with the role of the Ras pathway in schwannoma 
(Ammoun et al., 2008; Morrison et al., 2007).  The most enriched GO term overall 
corresponding to upregulated phospho-proteins is ‘AP-2 adaptor complex’, linked to clathrin-
mediated endocytosis. Among the downregulated phospho-proteins, there was significant 
enrichment of lysosomal proteins (Fig. S3). These are ARSA, AGA, CTSD, GUSB, PSAP 
and SMPD1. CTSD, or Cathepsin D, in particular is associated with caspase-3 induction of 
cell death and its downregulation may be related to schwannoma cell survival (Pranjol et al., 
2015).  
In order to identify proteins that were highly activated we wanted to identify those that 
displayed a relatively small change in protein abundance relative to phospho-protein 
expression. The simplest way of performing this analysis was to plot both datasets against 
each other as Log2FC, allowing for fast visual identification of the highly upregulated 
phospho-proteins (Fig. 1E). Fold changes of significantly changed phospho-proteins (p-value 
<0.05) are plotted on the y axis, against their respective protein fold changes (irrespective of 
p-value). The most relevant differences were found on the top part of the graph; among them 
we found several cytoskeletal-related proteins like PDLIM2, PDLIM5 and PDLIM7, the 
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regulator of cell polarity Rho-associated protein kinase 1 (ROCK1), Filamin-B and Vinculin. 
Numerous were also involved in vesicular transport like the alpha-soluble NSF attachment 
protein (NAPA), the Charged Multivascular Body Protein 2B (CHMP2B) and the Vacuolar 
Protein Sorting-associated 29 (VPS29). 
Differential protein and phospho-protein expression in Meningioma vs. Meningeal Cells 
Three primary human meningioma-derived cell populations (MN) and the meningioma cell 
line Ben Men-1 (Puttmann et al., 2005), were analysed against Human Meningeal Cells 
(HMC) as normal control. All samples were analysed for Merlin status by Western blot prior 
MS (Fig. 2A).   
In the comparison between grade I meningioma primary cells vs. HMC, 2582 proteins 
were identified (Table S4a) (peptides in table S4c), and after phospho-protein enrichment, we 
identified 2505 phospho-proteins (Table S4b) (peptides in table S4d) with a 6% overlap (Fig. 
S5b).  186 proteins were upregulated (Log2FC >-1) and 494 were downregulated (Log2FC <-
1) (Table S5). Of the identified phosphoproteins, 478 were significantly changed between the 
two cell types; 35 proteins were upregulated (Log2FC >-1) and 443 were downregulated 
(Log2FC <-1) (Table S6). Due to the relatively low number of significantly changed 
phosphoproteins (35), it was not feasible to detect statistically significant enriched GO and 
pathway terms by functional enrichment analysis in DAVID. We also tested the benign 
meningioma cell line and compared Ben Men-1 cells vs. HMC, grown and processed in 
triplicate separately and saw a 39% overlap between identified proteins and phosphoproteins 
(Fig. S5c). In this analysis 3129 proteins were identified (Table S7a) (peptides in table S7c), 
176 were significantly upregulated (Log2FC >-1), and 232 were significantly downregulated 
(Log2FC <-1) (Table S8). Among the most upregulated we found the tumour necrosis factor 
receptor superfamily member 10D (TNFRSF10D), and few integrins (ITGB3, ITGA8, 
ITGA4, ITGA1). The upregulated proteins were grouped based on protein class as before; a 
large number of them were nucleic acid binding (29%), cytoskeletal (17%) or receptor 
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proteins (14%) (Fig. 2B). GO enrichment analysis of upregulated proteins in the proteome 
dataset identified terms relating largely to ECM interaction, collagen and integrin mediated 
signalling (Fig. S4).  
After phospho-enrichment we identified 2770 proteins (Table S7b) (peptides in table S7d) 
and a total of 240 phospho-proteins were found significantly upregulated, whilst 195 were 
significantly downregulated (p<0.05, Log2FC>1/<-1, Table S9). The upregulated phospho-
proteins were submitted for functional enrichment analysis using DAVID. The top enriched 
pathways were spliceosome (25%), ribosome (13%) and cell cycle (13%) (Fig. 2C). 
Proteasome is represented by 11%, meaning a quite significant aberration in the protein 
degradation machinery, as well as antigen processing (11%), suggesting a possible impaired 
immune response. There was also significant representation of phospho-proteins involved in 
non-homologous end joining (NHEJ) (6%) and nucleotide excision repair (10%). The data 
therefore also indicates there may be alterations in DNA repair mechanisms. GO enrichment 
analysis identified significant enrichment of proteasome activator complex (80 fold) and 
proteasome activator activity (~60 fold), as well as positive regulation of ubiquitin-protein 
ligase activity, in line with functional enrichment analysis (Fig. 2D).  
Significantly changed phospho-proteins were plotted in a graph against their respective 
total protein abundancies (Fig. 2E). Among the most interesting phospho-proteins identified 
were transgelin-2 (TAGLN2), previously found overexpressed in meningioma (Sharma et al., 
2015); calcyclin binding protein (CACYBP), that can act as either an oncogene or a tumour 
suppressor depending on the type of cancer (Topolska-Wos et al., 2016); Deltex 3 like E3 
ubiquitin ligase (DTX3L), able to modulate DNA damage responses rendering cancer cells 
resistant to certain chemotherapy drugs (Thang et al., 2015). Interestingly, there were several 
phospho-proteins identified as downregulated that are related to organization of the 
cytoskeleton like Junction Plakoglobin (JUP), with a Log2FC = -20.663. Protein abundance 
was mostly unaltered indicating that decreased phosphorylation of JUP in tumour cells is 
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perhaps growth permissive. JUP, also known as γ-catenin is structurally and functionally 
related to β-catenin. Phosphorylated β-catenin was also found to be downregulated in Ben-
Men-1 cells.  
Schwannoma and Meningioma Common Phospho-proteins  
The amount of crossover between differentially expressed phospho-proteins in schwannoma 
vs. Schwann cells and in the Ben Men-1 vs. HMC datasets was as expected higher than with 
the primary meningioma cells vs. HMC dataset. In the analysis between significantly changed 
phospho-proteins in Ben Men-1 cells compared with those in primary schwannoma cells, 11 
were found commonly upregulated and 4 downregulated (Table 1). Thus we used this more 
informative dataset for comparison and subsequently verified expression in primary 
meningioma tumours. Among the commonly upregulated and activated proteins in both 
tumours we consistently find PDLIM2 and Filamin-B again. In addition, we identified the 
Epidermal growth factor receptor kinase Substrate 8-Like protein 2 (EPS8L2), that was found 
not highly expressed in the brain and links growth factor stimulation to cytoskeletal 
reorganization and the Ras/Rac pathway (Offenhauser et al., 2004), and the Signal 
Transducer and Activator of Transcription 1 alpha/beta (STAT1). The subunit beta type 8 and 
type 7 of the proteasome were also found commonly up- and downregulated respectively, 
again indicating proteasome dysregulation. We decided to perform initial validation studies 
on PDLIM2. This candidate was prioritised for the following reasons: 1. clear abnormalities 
in the cytoskeleton of these tumour cells (Flaiz et al., 2007; James et al., 2008); 2. we 
identified several upregulated proteins containing either a PDZ/LIM domain or both; 3. 
PDLIM2 acts both as an adaptor protein at the cytoskeletal level (Torrado et al., 2004) and an 
E3 ubiquitin ligase into the nucleus (Tanaka et al., 2007); previous studies identified 
CRL4(DCAF1), an E3 ubiquitin ligase important in schwannoma formation and related to 
Merlin (Li & Giancotti, 2010; Li et al., 2010), indicating that possibly the regulation of E3 
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ubiquitin ligases is pivotal in the pathogenesis of Merlin-deficient tumours; 4) PDLIM2 was 
also identified in primary meningioma with a log2 FC of 2.6 compared with HMC. 
PDLIM2 Is Overexpressed in Both Schwannomas and Meningiomas 
We analysed six schwannomas compared with normal human Schwann cells by Western blot. 
The protein was found overexpressed in four out of the six schwannomas compared to the 
normal Schwann cell examined (Schwann-0615) (Fig. 3A). A similar analysis was performed 
on meningiomas; we validated PDLIM2 overexpression in Ben Men-1 cells and in six 
tumour-derived primary cells compared to normal HMC (Fig. 3B). We also tested the level of 
PDLIM2 expression in tumour lysates compared to normal meninges (Fig. 3C). In all cases 
PDLIM2 was found overexpressed compared to normal cells or tissue. 
PDLIM2 Knockdown Highly Decreases Cellular Proliferation of Meningioma and 
Schwannoma Cells 
To investigate the functional relevance of PDLIM2 expression in schwannoma and 
meningioma we silenced PDLIM2 in three primary schwannomas and three primary 
meningiomas using shRNA lentiviral particles. PDLIM2 expression was significantly 
knocked down in schwannomas cells as confirmed by Western blot (Fig. 3D); this led to a 
significant reduction in ki-67 positive cells (p<0.001), reflecting a substantial reduction in 
proliferation in response to the knockdown (Fig. 3F).  
The same was repeated on meningioma cells and again we observed a reduction of protein 
expression after silencing (Fig. 3E) leading to a significant decrease in cellular proliferation 
as measured by a ki-67 proliferation assay (Fig. 3G). Altogether these data strongly suggest 
that PDLIM2 is involved in cellular proliferation in both schwannomas and meningiomas. 
PDLIM2 can be Phosphoprylated and Localises into the Nucleus of Schwannoma and 
Meningioma Cells  
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Quantitative proteomic analysis showed a statistically significant increase of PDLIM2 in 
Ben Men-1 cells compared to HMC after phospho-protein enrichment (Fig. 4A), suggesting a 
possible phosphorylated state of the protein. Unfortunately there are no specific phospho-
antibodies commercially available for pPDLIM2, so we performed an in vitro 
dephosphorylation assay using lambda phosphatase. The shift of the PDLIM2 
immunoreactive band after Western blot analysis indeed confirmed the phosphorylation on 
PDLIM2 (Fig. 4B). 
PDLIM2 was previously reported to act as a cytoplasmic protein (Torrado et al., 2004) 
and also as a nuclear protein (Tanaka et al., 2007), exhibiting different functions. To study 
the localization of PDLIM2 in our cellular models we performed cytoplasmic and nuclear 
protein extraction and examined by Western blot. PDLIM2 was found to localize largely into 
the nucleus (Fig. 4C) suggesting a possible function as E3 ubiquitin ligase as previously 
reported (Tanaka et al., 2007). We also performed immunofluorescent staining to further 
determine PDLIM2 localization and identified it both in the cytoplasm and the nucleus of 
BenMen-1 and primary meningioma cells (Fig. 4D and 4E).  
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Discussion  
The aim of this study was to decipher the proteome and phospho-proteome of Merlin-
deficient schwannomas and meningiomas relative to normal controls. Prior to this study, 
there was only one comparative analysis between meningioma and schwannoma at the 
genomic level reported in the literature (Torres-Martin et al., 2013b; Torres-Martin et al., 
2014).  
We first analysed proteome and phospho-proteome of schwannoma and meningioma 
separately, and compared them to their normal controls in order to identify proteins and 
phospho-proteins significantly differentially expressed in the two tumour types. Then, we 
merged the two sets of candidates identifying the common dysregulated proteins because in 
NF2 patients these tumours frequently occur together and need treatment. 
Our proteomic analysis was highly informative and revealed many proteins of potential 
interest in each dataset. However, despite the vast amount of information provided by this 
study there are also some limitations that have to be considered. Firstly, this research 
approach provides a general overview about dysregulated proteins and pathways; however, it 
is impossible to detect the whole proteome as non-abundant proteins cannot reach the level of 
detection. Secondly, phosphoproteomic studies require a large amount of starting material 
prior phospho-enrichment; schwannoma and especially human primary meningioma cells 
grow at slow rate for a limited number of passages (<7) making extremely difficult to obtain 
the required amount of proteins. Like every enrichment technique, there are possible false-
positives in the dataset and additional validation experiments are needed. The slow 
proliferation rate of our primary cells likely explain the reduced dataset obtained from the 
analysis of primary meningiomas which were cultured without the addition of external 
growth factors to avoid artificial manipulation of the protein signalling.  
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While proteome of whole tumour biopsies compared to normal meninges would provide 
information about environmental signals, here we decided to conduct the study on primary 
tumour cells and an established meningioma cell line, on which it was possible to perform 
subsequent functional validation. Using pure tumour cell populations instead of tissue also 
makes the comparison between tumours more meaningful as different tissue would vary in 
the tumour microenvironment. 
In schwannomas, by functional enrichment analysis, we identified several factors related 
to the cytoskeleton and its regulation, in line with the pivotal role of Merlin as cytoskeletal 
regulator (Gladden et al., 2010; Johnson et al., 2002; Lallemand et al., 2003; McClatchey & 
Giovannini, 2005). MAPK signalling was also found enriched, in agreement with previous 
studies (Ammoun et al., 2008; Fraenzer et al., 2003). Endocytosis, possibly clathrin-mediated, 
was listed among the upregulated pathways and cellular components in schwannoma, as well 
as the AP-2 adaptor complex required to internalize cargo in clathrin-mediated endocytosis 
(McMahon & Boucrot, 2011). This is in keeping with previous data in flies that showed 
Merlin is important for controlling membrane protein turnover in part by regulating 
endocytosis (Maitra et al., 2006). When the proteome and phospho-proteome were compared 
in order to identify highly activated proteins, we identified several cytoskeletal proteins like 
PDLIM2, Filamin B, Vinculin and the kinase ROCK1, a key regulator of the actin 
cytoskeleton and cell polarity, and previously associated with the ERM family (Hebert et al., 
2008). Again, we recognized proteins related to endocytosis and vesicle transport like 
PACSIN3, NAPA, CHMP2B and VPS29. 
As opposed to schwannomas, other driver mutations have been identified in meningioma, 
but those are mutually exclusive of Merlin (Clark et al., 2013). In order to keep the genetic 
background consistent with schwannoma, we analysed only Merlin-deficient WHO grade I 
meningiomas. Comparative functional enrichment analysis in the meningioma datasets 
identified pathways that might be of particular importance; among them we found 
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proteasome activation to be a recurring theme throughout, highlighting it as an important 
target in meningioma. A 2014 study looking at the proteasome inhibitor bortezomib showed 
that it was effective in sensitizing meningioma cells to TRAIL-induced apoptosis (Koschny et 
al., 2014). Further, the proteasome inhibitor MG132 was also found to increase levels of N-
cadherin in schwannoma cells, which in turn decreased proliferation (Zhou et al., 2011). Our 
data and previous reports thus suggest proteasome inhibition as a potential therapy, either 
alone or in combination with drugs targeting other relevant pathways. The phosphorylated 
protein with the largest fold change in primary meningioma cells was TGM2, or 
transglutaminase 2. The expression of this protein has been previously studied in meningioma 
and was found to be highly upregulated and suggested as a therapeutic target. The authors 
also showed that loss of the NF2 gene was associated with high expression of TGM2 (Huang 
et al., 2014). We also found TAGLN2 as upregulated in meningioma cells, in keeping with 
previous proteomic studies on meningioma (Sharma et al., 2015). It is similar in its function 
to transgelin (TAGLN), which we identified as highly expressed in schwannoma. The 
transgelins are a family of proteins able to influence a diverse range of cellular processes, 
including proliferation, migration and apoptosis (Dvorakova et al., 2014). The study by 
Sharma et al. used a similar proteomic approach to identify potential therapeutic targets using 
meningioma tissue (compared to normal brain) as opposed to cells. There were 12 proteins 
significantly upregulated and common to both datasets including the LIM domain containing 
protein FHL1, drebrin, fibronectin and translationally controlled tumor protein (TCTP), all 
linked with structural regulation. 
    We also identified possible alterations in DNA repair mechanisms, consistently with 
previous results showing chromosome instability  and defects in the mitotic apparatus in 
meningioma (van Tilborg et al., 2005), in particular in the NF2-mutated (Goutagny et al., 
2010). Studies by Yang and colleagues (2012) showed that the tumour suppressor CHEK2 on 
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chromosome 22q is often deleted together with Merlin, thus impairing DNA repair 
mechanisms and increasing chromosomal instability in meningiomas (Yang et al., 2012).  
Ben Men-1 cells, which have a known NF2 mutation, have been used as a WHO grade I 
meningioma cell line model and compared to HMC, bearing in mind possible modifications 
due to immortalization (Puttmann et al., 2005), however helping the study by being an 
homogeneous population of cells. The comparison between Ben Men-1 and schwannoma 
datasets compared with controls revealed several common upregulated proteins. Among them 
we identified the epidermal growth factor receptor kinase substrate 8-like protein 2 (EPS8L2), 
part of the EPS family of proteins related to actin cytoskeleton reorganization under growth 
factors stimulation (Offenhauser et al., 2004); the cytoskeletal protein Filamin-B (FLNB); 
and the signal transducer and activator of transcription 1-alpha/beta (STAT1), part of the 
JAK/STAT1 activated in response to interferon and previously found expressed in 
meningiomas (Magrassi et al., 1999), currently under validation.   
Here we decided to further analyse PDLIM2 for several reasons; we identified several 
PDZ/LIM domains proteins throughout the study, indicating a possibly important role of this 
family of proteins in Merlin-deficient tumours. PDLIM2 was first described in 2004 as an 
adaptor protein linking other proteins to the cytoskeleton (Torrado et al., 2004), so its 
dysregulation in Merlin-deficient tumours appeared highly plausible. Since, it has been found 
to have a number of different roles and has been particularly well studied in breast cancer 
where it has been identified as a driver of tumour progression and invasion (Deevi et al., 
2014; Loughran et al., 2005a). In 2007, for the first time PDLIM2 was shown to possess 
nuclear ubiquitin E3 ligase activity negatively regulating NF-kappaB by targeting the p65 
subunit during inflammation (Tanaka et al., 2007). Previous studies already identified another 
E3 ubiquitin ligase, CRL4(DCAF1), involved in the formation of Merlin-deficient tumours 
(Cooper et al., 2011; Li et al., 2010). Finally, the dysregulated ubiquitin ligase activity, 
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together with the dysregulated proteasomal activity found in meningiomas in our study, can 
suggest novel therapeutic strategies. 
We first confirmed PDLIM2 overexpression in primary meningioma and schwannoma 
samples and showed that it is not expressed in HMC or normal meningeal tissue and 
minimally expressed in the Schwann cell examined. PDLIM2 was significantly knocked 
down in three primary meningioma and three primary schwannoma cell populations. This led 
to significant reductions in cell proliferation in both cell types. These results are in line with a 
previous study which showed how PDLIM2 suppression leads to decreased proliferation in 
androgen-independent prostate cancer cell lines (Kang et al., 2016). On the other hand, other 
studies have identified PDLIM2 as an important tumour suppressor (Sun et al., 2015; Zhao et 
al., 2016). Interestingly enough, PDLIM5, that we found highly overexpressed in the 
schwannoma phospho-proteome, was found overexpressed in gastric cancer cells and its 
siRNA-mediated silencing significantly reduced cellular proliferation (Li et al., 2015), 
highlighting a possible common role for this family as regulators of cell proliferation.  
Our results showed that PDLIM2 can be phosphorylated. Recently one proteomic study 
identified specific phosphoserine sites on PDLIM2 (Bian et al., 2014); however, no 
phosphospecific antibodies are available and the result needs further validation. 
Upon subcellular fractionation, PDLIM2 was found to localise into the nucleus, possibly 
exploiting E3 ubiquitin ligase activity (Tanaka et al., 2007). ICC analysis showed it localised 
to both the nucleus and the cytoplasm. It may be that PDLIM2 associates with the 
cytoskeleton and is thus rendered insoluble during subcellular fractionation, as is the case 
with some cytoskeletal proteins e.g. intermediate filaments, explaining why only nuclear 
PDLIM2 was detectable via Western blot. Our overall results indicate that PDLIM2 has both 
nuclear and cytoplasmic functions in meningioma cells. Additional studies will be performed 
to verify whether the protein acts on p65 even in Merlin-negative meningiomas and 
schwannomas, and the role of the phosphorylation on PDLIM2 activity.  
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In conclusion, we performed a comprehensive analysis of proteome and phosphoproteome 
expression in Merlin-deficient schwannomas and meningiomas, found several dysregulated 
proteins/pathways in each dataset and underlying known and novel candidates involved in the 
pathogenesis of both tumours. Additionally, we validated the overexpression of PDLIM2 
which was found involved in the proliferation of both meningioma and schwannoma cells, 
confirming that  PDLIM2 warrants further investigation as a potential common target in 
Merlin-deficient meningiomas and schwannomas.  
26 
 
Acknowledgement 
We thank Dr. David Hilton for providing tumour specimens, the surgeons from Plymouth and 
Bristol hospitals and Dr. Emanuela Ercolano for helping with primary cell cultures. 
 
Funding sources 
This study was supported by grants from DHT (Dr. Hadwen Trust); Brain Tumour Research 
and the Biochemical Society (Eric Reid Fund for Methodology). 
  
27 
 
References 
Ammoun, S., Flaiz, C., Ristic, N., Schuldt, J., Hanemann, C. O., 2008. Dissecting and 
targeting the growth factor-dependent and growth factor-independent extracellular 
signal-regulated kinase pathway in human schwannoma. Cancer Res 68, 5236-5245. 
Ammoun, S., Provenzano, L., Zhou, L., Barczyk, M., Evans, K., Hilton, D. A., Hafizi, S.,  
Hanemann, C. O., 2014. Axl/Gas6/NFkappaB signalling in schwannoma pathological 
proliferation, adhesion and survival. Oncogene 33, 336-346. 
Bian, Y., Song, C., Cheng, K., Dong, M., Wang, F., Huang, J., Sun, D., Wang, L., Ye, M., 
Zou, H., 2014. An enzyme assisted RP-RPLC approach for in-depth analysis of human 
liver phosphoproteome. J Proteomics 96, 253-262. 
Bretscher, A., Chambers, D., Nguyen, R., Reczek, D., 2000. ERM-Merlin and EBP50 protein 
families in plasma membrane organization and function. Annu Rev Cell Dev Biol 16, 
113-143. 
Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Ozduman, K., Avşar, T., Li, J., 
Murray, P.B., Henegariu, O., Yilmaz, S., Günel, J.M., Carrión-Grant, G., Yilmaz, B., 
Grady, C., Tanrikulu, B., Bakircioğlu, M., Kaymakçalan, H., Caglayan, A.O., Sencar, L., 
Ceyhun, E., Atik, A.F., Bayri, Y., Bai, H., Kolb, L.E., Hebert, R.M., Omay, S.B., 
Mishra-Gorur, K., Choi, M., Overton, J.D., Holland, E.C., Mane, S., State, M.W., 
Bilgüvar, K., Baehring, J.M., Gutin, P.H., Piepmeier, J.M., Vortmeyer, A., Brennan, 
C.W., Pamir, M.N., Kiliç, T., Lifton, R.P., Noonan, J.P., Yasuno, K., Günel, M., 2013. 
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, 
and SMO. Science 339, 1077-1080. 
Claudio, J. O., Veneziale, R. W., Menko, A. S., Rouleau, G. A., 1997. Expression of 
schwannomin in lens and Schwann cells. Neuroreport 8, 2025-2030. 
Cooper, J., Li, W., You, L., Schiavon, G., Pepe-Caprio, A., Zhou, L., Ishii, R., Giovannini, 
M., Hanemann, C.O., Long, S.B., Erdjument-Bromage, H., Zhou, P., Tempst, P., 
28 
 
Giancotti FG., 2011. Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase 
CRL4DCAF1 to suppress oncogenic gene expression. Sci Signal 4, pt6. 
Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., Mann, M., 2014. Accurate 
proteome-wide label-free quantification by delayed normalization and maximal peptide 
ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13, 2513-2526. 
Curto, M., Cole, B. K., Lallemand, D., Liu, C. H., McClatchey, A. I., 2007. Contact-
dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 177, 893-903. 
Deevi, R. K., Cox, O. T., O'Connor, R., 2014. Essential function for PDLIM2 in cell 
polarization in three-dimensional cultures by feedback regulation of the beta1-integrin-
RhoA signaling axis. Neoplasia 16, 422-431. 
Dvorakova, M., Nenutil, R., Bouchal, P., 2014. Transgelins, cytoskeletal proteins implicated 
in different aspects of cancer development. Expert Rev Proteomics 11, 149-165. 
Fevre-Montange, M., Champier, J., Durand, A., Wierinckx, A., Honnorat, J., Guyotat, J.,  
Jouvet, A., 2009. Microarray gene expression profiling in meningiomas: differential 
expression according to grade or histopathological subtype. Int J Oncol 35, 1395-1407. 
Flaiz, C., Kaempchen, K., Matthies, C., Hanemann, C. O., 2007. Actin-rich protrusions and 
nonlocalized GTPase activation in Merlin-deficient schwannomas. J Neuropathol Exp 
Neurol 66, 608-616. 
Flaiz, C., Utermark, T., Parkinson, D. B., Poetsch, A., Hanemann, C. O., 2008. Impaired 
intercellular adhesion and immature adherens junctions in merlin-deficient human 
primary schwannoma cells. Glia 56, 506-515. 
Fraenzer, J. T., Pan, H., Minimo, L., Jr., Smith, G. M., Knauer, D., Hung, G., 2003. 
Overexpression of the NF2 gene inhibits schwannoma cell proliferation through 
promoting PDGFR degradation. Int J Oncol 23, 1493-1500. 
Garcia-Rendueles, M. E., Ricarte-Filho, J. C., Untch, B. R., Landa, I., Knauf, J.A., Voza, F., 
Smith, V.E., Ganly, I., Taylor, B.S., Persaud, Y., Oler, G., Fang, Y., Jhanwar, S.C., Viale,  
29 
 
A., Heguy, A., Huberman, K.H., Giancotti, F., Ghossein, R., Fagin, J.A., 2015. NF2 Loss 
Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent 
Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov 
5, 1178-1193. 
Gladden, A. B., Hebert, A. M., Schneeberger, E. E., McClatchey, A. I., 2010. The NF2 tumor 
suppressor, Merlin, regulates epidermal development through the establishment of a 
junctional polarity complex. Dev Cell 19, 727-739. 
Goutagny, S., Yang, H. W., Zucman-Rossi, J., Chan, J., Dreyfuss, J.M., Park, P.J., Black, 
P.M., Giovannini, M., Carroll, R.S., Kalamarides, M., 2010. Genomic profiling reveals 
alternative genetic pathways of meningioma malignant progression dependent on the 
underlying NF2 status. Clin Cancer Res 16, 4155-4164. 
Gronholm, M., Teesalu, T., Tyynela, J., Piltti, K., Bohling, T., Wartiovaara, K., Vaheri, A.,  
Carpen, O., 2005. Characterization of the NF2 protein merlin and the ERM protein ezrin 
in human, rat, and mouse central nervous system. Mol Cell Neurosci 28, 683-693. 
Guerrero, P. A., Yin, W., Camacho, L., Marchetti, D., 2015. Oncogenic role of Merlin/NF2 in 
glioblastoma. Oncogene 34, 2621-2630. 
Hanemann, C. O., Bartelt-Kirbach, B., Diebold, R., Kampchen, K., Langmesser, S., Utermark, 
T., 2006. Differential gene expression between human schwannoma and control 
Schwann cells. Neuropathol Appl Neurobiol 32, 605-614. 
 
Hanemann, C. O., 2008. Magic but treatable? Tumours due to loss of merlin. Brain 131, 606-
615. 
Hebert, M., Potin, S., Sebbagh, M., Bertoglio, J., Breard, J., Hamelin, J., 2008. Rho-ROCK-
dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in 
Jurkat cells. J Immunol 181, 5963-5973. 
30 
 
Huang da, W., Sherman, B. T., Lempicki, R. A., 2009. Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57. 
Huang, Y. C., Wei, K. C., Chang, C. N., Chen, P.Y., Hsu, P.W., Chen, C.P., Lu, C.S., Wang, 
H.L., Gutmann, D.H., Yeh, T.H., 2014. Transglutaminase 2 expression is increased as a 
function of malignancy grade and negatively regulates cell growth in meningioma. PLoS 
One 9, e108228. 
James, M. F., Lelke, J. M., Maccollin, M., Plotkin, S. R., Stemmer-Rachamimov, A. O., 
Ramesh, V., Gusella, J. F., 2008. Modeling NF2 with human arachnoidal and 
meningioma cell culture systems: NF2 silencing reflects the benign character of tumor 
growth. Neurobiol Dis 29, 278-292. 
Johnson, K. C., Kissil, J. L., Fry, J. L., Jacks, T., 2002. Cellular transformation by a FERM 
domain mutant of the Nf2 tumor suppressor gene. Oncogene 21, 5990-5997. 
Kaempchen, K., Mielke, K., Utermark, T., Langmesser, S., Hanemann, C. O., 2003. 
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. 
Hum Mol Genet 12, 1211-1221. 
Kang, M., Lee, K. H., Lee, H. S., Park, Y. H., Jeong, C. W., Ku, J. H., Kim, H. H., Kwak, C., 
2016. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human 
castration-resistant prostate cancer-like cells. Prostate 76, 273-285. 
Koschny, R., Boehm, C., Sprick, M. R., Haas, T.L., Holland, H., Xu, L.X., Krupp, W., 
Mueller, W.C., Bauer, M., Koschny, T., Keller, M., Sinn, P., Meixensberger, J., Walczak, 
H., Ganten, T.M., 2014. Bortezomib sensitizes primary meningioma cells to TRAIL-
induced apoptosis by enhancing formation of the death-inducing signaling complex. J 
Neuropathol Exp Neurol 73, 1034-1046. 
Lallemand, D., Curto, M., Saotome, I., Giovannini, M., McClatchey, A. I., 2003. NF2 
deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. 
Genes Dev 17, 1090-1100. 
31 
 
Lallemand, D., Manent, J., Couvelard, A., Watilliaux, A., Siena, M., Chareyre, F., Lampin, 
A., Niwa-Kawakita, M., Kalamarides, M., Giovannini, M., 2009. Merlin regulates 
transmembrane receptor accumulation and signaling at the plasma membrane in primary 
mouse Schwann cells and in human schwannomas. Oncogene 28, 854-865. 
Lasonder, E., Ishihama, Y., Andersen, J. S., Vermunt, A.M., Pain, A., Sauerwein, R.W., 
Eling W.M., Hall, N., Waters, A.P., Stunnenberg. H.G., Mann, M., 2002. Analysis of the 
Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 419, 537-
542. 
Lee, H., Hwang, S. J., Kim, H. R., Shin, C. H., Choi, K. H., Joung, J. G., Kim, H. H., 2016. 
Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-
dependent expression of CYR61/CCN1 and miR-296-3p. Biochim Biophys Acta 1859, 
599-611. 
Li, W. & Giancotti, F. G., 2010. Merlin's tumor suppression linked to inhibition of the E3 
ubiquitin ligase CRL4 (DCAF1). Cell Cycle 9, 4433-4436. 
Li, W., You, L., Cooper, J., Schiavon, G., Pepe-Caprio, A., Zhou, L., Ishii, R., Giovannini, 
M., Hanemann, C.O., Long, S.B., Erdjument-Bromage, H., Zhou, P., Tempst, P., 
Giancotti, F.G., 2010. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 
ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140, 477-490. 
Li, W., Cooper, J., Zhou, L., Yang, C., Erdjument-Bromage, H., Zagzag, D., Snuderl, M., 
Ladanyi, M., Hanemann, C.O., Zhou, P., Karajannis, M.A., Giancotti, F.G. 2014. 
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of 
the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 26, 48-60. 
Li, Y., Gao, Y., Xu, Y., Sun, X., Song, X., Ma, H., Yang, M., 2015. si-RNA-mediated 
knockdown of PDLIM5 suppresses gastric cancer cell proliferation in vitro. Chem Biol 
Drug Des 85, 447-453. 
32 
 
Loughran, G., Healy, N. C., Kiely, P. A., Huigsloot, M., Kedersha, N. L., O'Connor, R., 
2005a. Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain 
protein that promotes cell attachment and migration and suppresses Anchorage-
independent growth. Mol Biol Cell 16, 1811-1822. 
Loughran, G., Huigsloot, M., Kiely, P. A., Smith, L. M., Floyd, S., Ayllon, V., O'Connor, R., 
2005b. Gene expression profiles in cells transformed by overexpression of the IGF-I 
receptor. Oncogene 24, 6185-6193. 
Magrassi, L., De-Fraja, C., Conti, L., Butti, G., Infuso, L., Govoni, S., Cattaneo, E., 1999. 
Expression of the JAK and STAT superfamilies in human meningiomas. J Neurosurg 91, 
440-446. 
Maitra, S., Kulikauskas, R. M., Gavilan, H., Fehon, R. G., 2006. The tumor suppressors 
Merlin and Expanded function cooperatively to modulate receptor endocytosis and 
signaling. Curr Biol 16, 702-709. 
Martin, K., Rossi, V., Ferrucci, S., Pian, D., 2010. Retinal astrocytic hamartoma. Optometry 
81, 221-233. 
Maudsley, S., Zamah, A. M., Rahman, N., Blitzer, J. T., Luttrell, L. M., Lefkowitz, R. J., Hall, 
R. A., 2000. Platelet-derived growth factor receptor association with Na(+)/H(+) 
exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 20, 8352-8363. 
McClatchey, A. I., 2003. Merlin and ERM proteins: unappreciated roles in cancer 
development? Nat Rev Cancer 3, 877-883. 
McClatchey, A. I., Giovannini, M., 2005. Membrane organization and tumorigenesis--the 
NF2 tumor suppressor, Merlin. Genes Dev 19, 2265-2277. 
McMahon, H. T., Boucrot, E., 2011. Molecular mechanism and physiological functions of 
clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12, 517-533. 
Meimoun, P., Ambard-Bretteville, F., Colas-des Francs-Small, C., Valot, B., Vidal, J., 2007. 
Analysis of plant phosphoproteins. Anal Biochem 371, 238-246. 
33 
 
Mohler, P. J., Kreda, S. M., Boucher, R. C., Sudol, M., Stutts, M. J., Milgram, S. L., 1999. 
Yes-associated protein 65 localizes p62(c-Yes) to the apical compartment of airway 
epithelia by association with EBP50. J Cell Biol 147, 879-890. 
Morrison, H., Sperka, T., Manent, J., Giovannini, M., Ponta, H., Herrlich, P., 2007. 
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras 
and Rac. Cancer Res 67, 520-527. 
Morrow, K. A., Das, S., Meng, E., Menezes, M. E., Bailey, S. K., Metge, B. J., Buchsbaum, 
D. J., Samant, R. S., Shevde, L. A., 2016. Loss of tumor suppressor Merlin results in 
aberrant activation of Wnt/beta-catenin signaling in cancer. Oncotarget 7, 17991-18005. 
Offenhauser, N., Borgonovo, A., Disanza, A., Romano, P., Ponzanelli, I., Iannolo, G., Di 
Fiore, P. P., Scita, G., 2004. The eps8 family of proteins links growth factor stimulation 
to actin reorganization generating functional redundancy in the Ras/Rac pathway. Mol 
Biol Cell 15, 91-98. 
Pranjol, M. Z., Gutowski, N., Hannemann, M., Whatmore, J., 2015. The Potential Role of the 
Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial 
Ovarian Cancer. Biomolecules 5, 3260-3279. 
Puttmann, S., Senner, V., Braune, S., Hillmann, B., Exeler, R., Rickert, C. H., Paulus, W., 
2005. Establishment of a benign meningioma cell line by hTERT-mediated 
immortalization. Lab Invest 85, 1163-1171. 
Qu, Z., Fu, J., Yan, P., Hu, J., Cheng, S. Y., Xiao, G., 2010. Epigenetic repression of PDZ-
LIM domain-containing protein 2: implications for the biology and treatment of breast 
cancer. J Biol Chem 285, 11786-11792. 
Rappsilber, J., Ishihama, Y., Mann, M., 2003. Stop and go extraction tips for matrix-assisted 
laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in 
proteomics. Anal Chem 75, 663-670. 
34 
 
Rouleau, G. A., Merel, P., Lutchman, M., Rouleau, G.A., Merel, P., Lutchman, M., Sanson, 
M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, 
B., et al., 1993. Alteration in a new gene encoding a putative membrane-organizing 
protein causes neuro-fibromatosis type 2. Nature 363, 515-521. 
Sakuda, K., Kohda, Y., Matsumoto, T., Park, C., Seto, A., Tohma, Y., Hasegawa, M., Kida, 
S., Nitta, H., Yamashima, T., Yamashita J., 1996. Expression of NF2 gene product 
merlin in arachnoid villi and meningiomas. Noshuyo Byori 13, 145-148. 
Scherer, S. S., Gutmann, D. H., 1996. Expression of the neurofibromatosis 2 tumor 
suppressor gene product, merlin, in Schwann cells. J Neurosci Res 46, 595-605. 
Schulze, K. M., Hanemann, C. O., Muller, H. W., Hanenberg, H., 2002. Transduction of 
wild-type merlin into human schwannoma cells decreases schwannoma cell growth and 
induces apoptosis. Hum Mol Genet 11, 69-76. 
Sharma, S., Ray, S., Moiyadi, A., Sridhar, E., Srivastava, S., 2014. Quantitative proteomic 
analysis of meningiomas for the identification of surrogate protein markers. Sci Rep 4, 
7140. 
Sharma, S., Ray, S., Mukherjee, S., Moiyadi, A., Sridhar, E., Srivastava, S., 2015. 
Multipronged quantitative proteomic analyses indicate modulation of various signal 
transduction pathways in human meningiomas. Proteomics 15, 394-407. 
Sheikh, H. A., Tometsko, M., Niehouse, L., Aldeeb, D., Swalsky, P., Finkelstein, S., Barnes, 
E. L., Hunt, J. L., 2004. Molecular genotyping of medullary thyroid carcinoma can 
predict tumor recurrence. Am J Surg Pathol 28, 101-106. 
Sun, F., Xiao, Y., Qu, Z., 2015. Oncovirus Kaposi sarcoma herpesvirus (KSHV) represses 
tumor suppressor PDLIM2 to persistently activate nuclear factor kappaB (NF-kappaB) 
and STAT3 transcription factors for tumorigenesis and tumor maintenance. J Biol Chem 
290, 7362-7368. 
35 
 
Tanaka, T., Grusby, M. J., Kaisho, T., 2007. PDLIM2-mediated termination of transcription 
factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 
subunit. Nat Immunol 8, 584-591. 
Te Velthuis, A. J., Isogai, T., Gerrits, L., Bagowski, C. P., 2007. Insights into the molecular 
evolution of the PDZ/LIM family and identification of a novel conserved protein motif. 
PLoS One 2, e189. 
Thang, N. D., Yajima, I., Kumasaka, M. Y., Iida, M., Suzuki, T., Kato, M., 2015. Deltex-3-
like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not 
MEK/ERK pathway. Oncotarget 6, 14290-14299. 
Topolska-Wos, A. M., Chazin, W. J., Filipek, A., 2016. CacyBP/SIP--Structure and variety of 
functions. Biochim Biophys Acta 1860, 79-85. 
Torrado, M., Senatorov, V. V., Trivedi, R., Fariss, R. N.,Tomarev, S. I., 2004. Pdlim2, a 
novel PDZ-LIM domain protein, interacts with alpha-actinins and filamin A. Invest 
Ophthalmol Vis Sci 45, 3955-3963. 
Torres-Martin, M., Lassaletta, L., de Campos, J. M., Isla, A., Gavilan, J., Pinto, G.R., 
Burbano, R.R., Latif, F., Melendez, B., Castresana, J.S., Rey, J.A., 2013a. Global 
profiling in vestibular schwannomas shows critical deregulation of microRNAs and 
upregulation in those included in chromosomal region 14q32. PLoS One 8, e65868. 
Torres-Martin, M., Lassaletta, L., San-Roman-Montero, J., De Campos, J.M., Isla, A., 
Gavilan, J., Melendez, B., Pinto, G.R., Burbano, R.R., Castresana, J.S., Rey, J.A., 2013b. 
Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET 
signaling pathway and androgen receptor deregulation. Int J Oncol 42, 848-862. 
Torres-Martin, M., Lassaletta, L., Isla, A., De Campos, J. M., Pinto, G. R., Burbano, R. R., 
Castresana, J. S., Melendez, B., Rey, J. A., 2014. Global expression profile in low grade 
meningiomas and schwannomas shows upregulation of PDGFD, CDH1 and SLIT2 
compared to their healthy tissue. Oncol Rep 32, 2327-2334. 
36 
 
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., Cox, J.,  
2016. The Perseus computational platform for comprehensive analysis of (prote)omics 
data. Nat Methods. 
van Tilborg, A. A., Al Allak, B., Velthuizen, S. C., de Vries, A., Kros, J. M., Avezaat, C. J., 
de Klein, A., Beverloo, H. B., Zwarthoff, E. C., 2005. Chromosomal instability in 
meningiomas. J Neuropathol Exp Neurol 64, 312-322. 
Wang, X., Gong, Y., Wang, D., Xie, Q., Zheng, M., Zhou, Y., Li, Q., Yang, Z., Tang, H., Li, 
Y., Hu, R., Chen, X., Mao, Y., 2012. Analysis of gene expression profiling in 
meningioma: deregulated signaling pathways associated with meningioma and EGFL6 
overexpression in benign meningioma tissue and serum. PLoS One 7, e52707. 
Weinman, E. J., Steplock, D., Donowitz, M., Shenolikar, S., 2000. NHERF associations with 
sodium-hydrogen exchanger isoform 3 (NHE3) and ezrin are essential for cAMP-
mediated phosphorylation and inhibition of NHE3. Biochemistry 39, 6123-6129. 
Yang, H. W., Kim, T. M., Song, S. S., Shrinath, N., Park, R., Kalamarides, M., Park, P.J., 
Black, P.M., Carroll, R.S., Johnson, M.D., 2012. Alternative splicing of CHEK2 and 
codeletion with NF2 promote chromosomal instability in meningioma. Neoplasia 14, 20-
28. 
Zhang, Y., Wen, Z., Washburn, M. P., Florens, L., 2009. Effect of dynamic exclusion 
duration on spectral count based quantitative proteomics. Anal Chem 81, 6317-6326. 
Zhao, B., Li, L., Lei, Q., Guan, K. L., 2010. The Hippo-YAP pathway in organ size control 
and tumorigenesis: an updated version. Genes Dev 24, 862-874. 
Zhao, L., Yu, C., Zhou, S., Lau, W.B., Lau, B., Luo, Z., Lin, Q., Yang, H., Xuan, Y., Yi, T., 
Zhao, X., Wei, Y., 2016. Epigenetic repression of PDZ-LIM domain-containing protein 2 
promotes ovarian cancer via NOS2-derived nitric oxide signaling. Oncotarget 7, 1408-
1420. 
37 
 
Zhou, L., Ercolano, E., Ammoun, S., Schmid, M. C., Barczyk, M. A., Hanemann, C. O., 2011. 
Merlin-deficient human tumors show loss of contact inhibition and activation of 
Wnt/beta-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia 
13, 1101-1112. 
 
  
38 
 
FIGURE LEGENDS 
 
FIGURE 1 
Functional comparative analysis of schwannoma vs. normal Schwann cells. (A) Western 
blot showing Merlin expression in normal human Schwann cells and loss of Merlin 
expression in schwannomas. (B) Pie chart, created using PANTHER.db, showing the 
upregulated proteins grouped based on protein class. About 50% of the total upregulated 
proteins in schwannomas were cytoskeletal. (C) Pie chart showing the upregulated phospho-
proteins submitted for functional enrichment analysis using DAVID, the figure highlights a 
number of activated pathways in schwannoma cells but not in normal Schwann cells. Focal 
adhesion and MAPK signalling were the most enriched (18% and 16% respectively). (D) 
Most significantly enriched GO terms in the protein classes ‘molecular function’ (green), 
‘cellular component’ (blue) and ‘biological process’ (red). As cellular component, the AP-2 
adaptor complex was found highly enriched (about 80%) as well as clathrin-mediated 
endocytosis (nearly 70% and 50%) (E) Significantly changed phospho-proteins in 
schwannoma cells vs. phospho-proteins in normal Schwann cells plotted against their 
respective protein and phospho-protein amounts. Data were plotted as a Log2FC LFQ 
tumour/normal. 
FIGURE 2 
Functional comparative analysis of meningioma cells vs. normal HMC. (A) Western blot 
showing Merlin expression in normal HMC and no Merlin expression in meningioma 
tumour-derived cells. (B) Pie chart representing the upregulated proteins, grouped based on 
protein class (PANTHER.db). The top three upregulated protein classes in meningioma were 
related to nucleic acid binding (29%), the cytoskeleton (17%) and membrane receptors (14%). 
(C) Pie chart presentation of the upregulated phospho-proteins submitted for functional 
enrichment analysis using DAVID, the figure highlights a number of activated pathways in 
meningioma cells but not in normal meningeal cells. (D) Most significantly enriched GO 
terms in the protein classes ‘molecular function’ (green), ‘cellular component’ (blue) and 
‘biological process’ (red). Among them the proteasome was found the most enriched cellular 
component (about 80%) and biological process (nearly 60%). (E) Significantly changed 
phospho-proteins in Ben Men-1 cells vs. phospho-proteins in normal HMC plotted against 
their respective protein and phospho-protein amounts. Data were plotted as a Log2FC LFQ 
tumour/normal. 
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FIGURE 3 
PDLIM2 overexpressed in schwannomas and meningiomas is linked to increased 
proliferation of tumour cells. (A) Western blot analysis of PDLIM2 expression in primary 
schwannoma cells compared to primary human Schwann cell. (B-C) Western blot analysis of 
PDLIM2 expression in Ben Men-1 and primary meningioma cells compared to HMC (B), 
and meningioma tumour specimens compared to normal human meninges (C). (D) PDLIM2 
shRNA-mediated knockdown in three primary schwannomas, confirmed by the absence of 
immunoreactive band in Western blot analysis compared to the sh-scramble control. The 
samples analysed were; (1) NF1: NF1115 (Fig 3A), Merlin-positive and pMerlin-positive, 
NF0116; (2) NF2: NF0116, Merlin-positive and pMerlin faint band (data not shown); (3) 
NF3: NF0216, Merlin-negative and pMerlin-negative (data not shown).  (E) PDLIM2 
shRNA-mediated knockdown in three primary meningioma cells, confirmed by the reduction 
of intensity of the immunoreactive band detected by Western blot analysis compared to the 
sh-Scramble control. The samples analysed were; (1) MN1: MN026, Merlin-negative and 
pMerlin-negative (data not shown), (2) MN2: MN028, and (3) MN3: MN031, both Merlin-
negative and pMerlin-negative (Fig. 3B).  (F) Ki-67 immunofluorescent staining (green) of 
the three schwannoma cell populations after PDLIM2 shRNA knockdown compared to sh-
Scramble control. On the left side the histogram showing the highly statistically significant 
(, p<0.001) reduced proliferation in PDLIM2 knockdown cells. (G) Ki-67 
immunofluorescent staining (green) of the three primary meningioma cells after PDLIM2 
shRNA knockdown compared to sh-Scramble control. On the left side the histogram showing 
the statistically significant (, p<0.05) reduced proliferation in PDLIM2 knockdown cells. 
Nuclei are stained with DAPI (Blue). Micrographs are taken at 20X magnification. SC-
Scramble; KD-knockdown. 
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FIGURE 4 
PDLIM2 acts as phosphoprotein and localises into the nucleus. (A) Histogram showing 
PDLIM2 MS quantification as Log2 LFQ value in Ben Men-1 (BM) cells vs. HMC after 
phosphoenrichment. Phosphorylated PDLIM2 was statistically significantly enriched in Ben 
Men-1 cells (, p<0.012) compared to HMC. (B) Western blot analysis confirming the 
phosphorylated status of PDLIM2 in Ben Men-1 cells. Lambda phosphatase treatment (-Ph) 
induced indeed a shift in PDLIM2 immunoreactive band compared to non-treated (NT) 
control. (C) Representative Western blot showing PDLIM2 localization after nuclear and 
cytoplasmic protein fractionation. Total HDAC1 and GAPDH are shown as reference protein 
for the nuclear and cytoplasmic fraction respectively. (D) Confocal microscopy (Z-stacks) of 
PDLIM2 (red) in Ben Men-1 cells and in primary meningioma cells (MN028, MN033, 
MN036) (E). Nuclei were stained with DAPI (blue). 
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Table 1. Phospho-proteins commonly and significantly up- or downregulated in Ben Men-1 
and primary schwannoma cells (p<0.05) 
 
 
Gene 
symbol Protein name 
Log2FC 
meningioma 
Log2FC 
schwannoma 
CORO1C Coro nin-1C 2.60 1.45 
CTPS CTP synthase 1 1.23 3.70 
CUTA Protein CutA 1.44 1.50 
EPS8L2 Epidermal growth factor receptor kinase 
substrate 8-like protein 2 
3.36 24.27 
FLNB Filamin-B 1.22 24.49 
HSPA1A Heat shock 70 kDa protein 1A/1B 1.21 3.23 
PDE1C Calcium/calmodulin-dependent 3,5-cyclic 
nucleotide phosphodiesterase 1C 
3.16 1.36 
PDLIM2 PDZ and LIM domain protein 2 3.94 24.53 
PSMB8 Proteasome subunit beta type-8 1.40 1.29 
STAT1 Signal transducer and activator of 
transcription 1-alpha/beta 
4.57 26.24 
TCEB2 Transcription elongation factor B 
polypeptide 2 
1.01 1.02 
MAP1A Microtubule-associated protein 1A − 19.89 − 1.00 
PACSIN2 Protein kinase C and casein kinase 
substrate in neurons protein 2 
− 2.11 − 1.19 
PSMB7 Proteasome subunit beta type-7 − 1.17 − 1.32 
UFL1 E3 UFM1-protein ligase 1 − 1.14 − 1.43 
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Graphical Abstract 
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Highlights 
 Proteome and phosphoproteome of Merlin-deficient schwannomas and meningiomas was 
analysed.  
 Comparative studies highlighted several pathways relevant for therapeutic intervention. 
 PDLIM2 was identified as a novel, commonly upregulated protein in both tumours. 
 PDLIM2 knockdown led to a significant reduction in proliferation in both cell types. 
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Lay summary  
 
Loss or mutation of the protein Merlin causes a genetic condition known as 
Neurofibromatosis 2 (NF2) characterised by the growth of schwannomas and meningiomas.  
We analysed several of these tumour samples and identified over 2000 proteins in 
comparative experiments between Merlin-deficient schwannoma and meningioma compared 
to normal controls. We identified PDZ and LIM domain protein 2 (PDLIM2) as 
overexpressed in both tumour types and further showed that knockdown of PDLIM2 leads to 
significant reductions in cellular proliferation. 
Taken together, our data highlight several deregulated signalling pathways, and indicate that 
PDLIM2 may represent a novel, common target for meningioma and schwannoma.  
 
 
Key words  
Schwannoma; Meningioma; PDLIM2; Phosphoproteomics; Translational  
 
 
 
 
 
 
 
 
 
  
49 
 
Supplemental Figures 
 
 
FIGURE S1 
Representative steps involved in target identification used in the study. 
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FIGURE S2 
Protein interaction analysis performed using string.db (string-db.org), highlighting 
interactions between the 16 proteins upregulated in schwannoma with a Log2FC >1. 
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FIGURE S3 
GO analysis of phosphoproteins downregulated in schwannoma cells compared to normal 
Schwann cells. ‘Microtubule polarization’ was the highest downregulated among the 
‘biological process’ class (~40%) (red). 
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FIGURE S4 
GO analysis of upregulated total proteins in the dataset Ben Men-1 cells vs. HMC. Collagen 
binding and organization was found among the highly represented with over 40 folds 
enrichment as ‘Cellular component’ (blue), and about 20 folds enrichment as ‘Molecular 
function’ (green) and ‘Biological process’ (red). ‘Platelet-derived growth factor binding’ was 
the highest enriched ‘Molecular function’ with over 40 folds increase. 
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FIGURE S5 
Venn diagrams representing the overlap between proteins and phosphoproteins in the 
schwannoma vs. Schwann cells dataset (A), in the grade I meningioma primary cells vs. 
HMC dataset (B) and in the Ben Men-1 vs. HMC dataset (C). 
 
 
 
